---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-022385"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:11:54.397415+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rallybio CMO Steven Ryder departs immediately; severance tied to pending Candid merger

## Summary
- Steven Ryder, M.D., Chief Medical Officer, leaves Rallybio effective March 31, 2026.
- Severance includes payments for without-cause termination; additional contingent on Candid merger close.
- Equity awards remain outstanding and vest per Merger Agreement; exercisable 90 days post-close.
- Pending business combination with Candid Therapeutics announced March 1, 2026.

## SEC filing metadata
- accession: 0001628280-26-022385
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/0001628280-26-022385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/rlyb-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-022385
- JSON: https://secwatch.observer/filing/0001628280-26-022385.json
- Plain text: https://secwatch.observer/filing/0001628280-26-022385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.